Neurological7 residues

Semax

ACTH-fragment analogue

Semax is an ACTH-fragment analogue investigated in neurological research. This entry concentrates on a primary rat study of neurotrophin gene expression and its limits.

Reviewed September 2026

Residues
7. calculated: Count of residues in the stored canonical reference sequence; terminal groups are not extra residues.
Average mass
813.92 Da. calculated: Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded.
pI
5.22 (theoretical). calculated: Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation.

Primary structure

Sequence

N-terminusC-terminus
MethionineMet · MOpen amino-acid reference

Peptide. Sequence describes the reference peptide, not a tested supplier lot.

Calculated properties

Calculated from the sequence
FormulaC37H51N9O10S
Monoisotopic mass813.3480 Da
Extinction coefficient at 280 nmNone (no Tyr or Trp)
A280 at 1 mg/mLNot measurable
Residues7
Average mass813.92 Da
pI5.22 (theoretical)
Identity
AliasesACTH-fragment analogue
SequenceMEHFPGP
Research areaNeurological

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

Calculation scope: the stored canonical amino-acid sequence with free N- and C-termini, no other modifications or counterions. This specifies a reference form, not the chemical form or identity of a sold lot.

  • Residues: 7 (calculated). Count of residues in the stored canonical reference sequence; terminal groups are not extra residues. Residues source 1
  • Average mass: 813.92 Da (calculated). Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded. Average mass source 1 Average mass source 2 Average mass source 3
  • pI: 5.22 (theoretical) (calculated). Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation. pI source 1 pI source 2

Residue composition

Unique residues
6
Most common
Proline
Nonpolar residues
0
Other classified residues
7

Proline is the most common residue (2). The calculated charge at pH 7 is net negative (-0.92).

Reference scope and linked records

Reference type: Peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: Semax. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Neurotrophin gene expression in rat brain under the action of Semax. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About Semax

Identity and context

The peptide is described by the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is not full-length ACTH and should not be treated as chemically identical to Selank or to products described only as modified Semax analogues.

Reference classification

Peptide. The linked catalogue product is Semax. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Confirm the exact peptide and any terminal modification. Keep unmodified Semax, acetylated derivatives and incompletely specified analogue names separate in the experiment and source record.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesA primary study measured rapid changes in NGF and BDNF gene expression across regions of normal rat brain. The response varied by gene and brain region, including increases in some regions and a decrease in frontal-cortex NGF expression. A single slogan such as increases BDNF would leave out important experimental context.Source context
What cannot be inferredThese measurements are not proof of cognitive enhancement or recovery from a neurological condition in humans. They also do not identify Adamax or demonstrate the behaviour of a purported Semax derivative.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Neurotrophin gene expression in rat brain under the action of SemaxPrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.